Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ANI Pharmaceuticals, Inc. (Nasdaq: ANIP), a diversified biopharmaceutical company focused on rare disease, generics, and branded therapeutics. Through these filings, investors can review how ANI reports its financial results, capital structure changes, and other material events related to its Rare Disease, Generics, and Brands businesses.
ANI frequently files Form 8-K current reports to disclose quarterly and year-to-date financial results, updated investor presentations, and other significant developments. For example, recent 8-K filings reference press releases announcing results for specific quarters, updated guidance, and the publication of investor presentations that describe the company’s strategy, segment performance, and focus on products such as Purified Cortrophin Gel and ILUVIEN. Other 8-K filings discuss matters like the conversion of Series A Convertible Preferred Stock into common shares and updates on litigation outcomes.
In addition to 8-Ks, investors can use this filings page to locate ANI’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide more detailed discussions of segment results, risk factors, product portfolios, and the company’s rare disease strategy. These periodic reports elaborate on how ANI’s Rare Disease, Generics, and Brands businesses contribute to overall performance and outline risks related to manufacturing, regulatory approvals, competition, and market conditions.
Filings related to equity and capital structure are also important for ANIP. For instance, the company has reported on the issuance and subsequent conversion of Series A Convertible Preferred Stock, including dividend terms and conversion conditions, and on the issuance of common shares upon conversion under exemptions from registration. Such disclosures help investors understand changes in outstanding securities and potential dilution.
Stock Titan enhances this information by offering AI-powered summaries of ANI’s key filings. These summaries highlight the main points from lengthy documents, such as revenue trends, segment performance, major product updates, and notable legal or corporate events. Users can quickly scan 10-Ks, 10-Qs, and 8-Ks, and then dive into the full text on EDGAR for deeper analysis. The filings page also surfaces information relevant to insider and security-holder activity where reported, enabling a more complete view of ANI Pharmaceuticals’ regulatory and financial disclosures.
ANI Pharmaceuticals Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report it beneficially owns 0 shares of ANI Pharmaceuticals Inc common stock, representing 0%. The filing states an internal realignment on January 12, 2026 led certain Vanguard subsidiaries to report separately under SEC Release No. 34-39538.
ANI Pharmaceuticals senior executive sells part of stake
ANI Pharmaceuticals’ SVP, Head – Established Brands, Thomas Andrew Rowland, reported an open-market sale of 4,772 shares of common stock at an average price of $74.91 per share. After this transaction, he directly holds 38,730 shares, indicating a partial sale while retaining a significant remaining position.
ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported an open-market sale of 3,162 shares of Common Stock. The shares were sold on March 13, 2026 at a weighted average price of $71.64 per share, in multiple trades ranging from $70.27 to $72.62.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following this sale, Mutz directly holds 91,309 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported a small open-market sale of 500 shares of common stock at $72.62 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025.
After this sale, Cook still directly owns 79,390 shares, so the trade represents a minor portion of her overall reported holdings and appears to be a routine, pre-planned liquidity event rather than a major change in ownership.
ANI Pharmaceuticals executive Christopher Mutz reported recent stock transactions in ANI PHARMACEUTICALS INC common shares. He sold 2,121 shares on March 6, 2026 at $74.22 per share and 3,602 shares on March 9, 2026 at $74.18 per share, both as open‑market sales under a Rule 10b5‑1 trading plan adopted on June 16, 2025. Separately, 3,314 shares were withheld on March 7, 2026 at $74.04 per share to cover tax obligations tied to the vesting of 6,476 restricted shares. After these transactions, he directly holds 94,471 shares of ANI common stock.
ANI Pharmaceuticals President & CEO Nikhil Lalwani reported a tax-related share disposition. On the reported date, 17,060 shares of common stock were withheld at a price of $74.04 per share to cover tax obligations tied to the vesting of 33,352 previously granted restricted shares.
These withheld shares were not an open-market sale but a payment of tax liability. After this withholding, Lalwani directly owned 404,889 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP, Generics Ori Gutwerg had 3,314 shares of Common Stock withheld on March 7, 2026 to cover tax obligations at $74.04 per share. The shares were tied to the vesting of 6,476 restricted shares, and Gutwerg now holds 81,468 shares directly.
ANI Pharmaceuticals senior executive Krista Davis reported open-market sales of company stock. As SVP and Chief HR Officer, she sold 6,572 shares of ANI Pharmaceuticals common stock in two transactions at prices of $74.13 and $75.00 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating they were scheduled in advance rather than timed discretionarily. Following the transactions, Davis directly holds 51,946 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported a tax-related share disposition. On the vesting of 11,292 shares of restricted stock that had been granted earlier, 5,150 shares of common stock were withheld at $74.04 per share to cover tax obligations, a non-market transaction exempt under Rule 16(b)-3. After this withholding, Carey directly holds 180,393 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and CFO Stephen P. Carey reported both an option exercise and share sales. He exercised options for 3,312 shares at $49.51 per share, then sold a total of 7,312 common shares in open‑market trades at prices around $75.42–$75.56. Following these transactions, he directly holds 185,543 shares of common stock and 9,938 stock options.